Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Dazodalibep in Sjögren's Syndrome
NCT06747949Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Feb 2025
- Primary completion
- Dec 2029
- Modality
- Fc-Fusion Proteins
- Countries
- 26
01
Overview
Phase 3, open-label, single-arm trial of dazodalibep in Sjögren's syndrome, sponsored by Amgen. Primary endpoint: Number of Participants with Treatment-emergent Adverse Events at 152 weeks. Started Feb 2025; status: recruiting.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT06747949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747949.